These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33035714)

  • 1. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
    Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
    Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder.
    Chang HY; Daubresse M; Saloner B; Alexander GC
    Med Care; 2019 Sep; 57(9):667-672. PubMed ID: 31404013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
    Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
    Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
    J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.
    Alexandridis AA; Dasgupta N; Ringwalt CL; Rosamond WD; Chelminski PR; Marshall SW
    PLoS One; 2020; 15(1):e0227350. PubMed ID: 31923197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder.
    Varisco T; Shen C; Thornton D
    J Subst Abuse Treat; 2020 Oct; 117():108073. PubMed ID: 32811630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
    Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
    JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency.
    Paiva TJ; Wightman RS; St John K; Nitenson AZ; Onyejekwe C; Hallowell BD
    J Subst Use Addict Treat; 2024 Jul; 162():209382. PubMed ID: 38677597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals.
    Al Faysal J; Noor-E-Alam M; Young GJ; Lo-Ciganic WH; Goodin AJ; Huang JL; Wilson DL; Park TW; Hasan MM
    Comput Biol Med; 2024 Jul; 177():108493. PubMed ID: 38833799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.
    Thakrar AP; Christine PJ; Siaw-Asamoah A; Spadaro A; Faude S; Snider CK; Delgado MK; Lowenstein M; Kampman K; Perrone J; Nelson LS; Kilaru AS
    JAMA Netw Open; 2024 Sep; 7(9):e2435895. PubMed ID: 39331392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.
    Hooker SA; Starkey C; Bart G; Rossom RC; Kane S; Olson AW
    BMC Prim Care; 2024 Oct; 25(1):361. PubMed ID: 39394565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Larochelle MR
    J Subst Abuse Treat; 2022 Feb; 133():108540. PubMed ID: 34148756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.